Cordis to Receive $1.725 Billion

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Wall Street Capital Funding.

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by the Paragon Financial Report

See the rest of the story here.

Theflyonthewall.com is Wall Street's specialist in breaking equity news. Veteran traders build a proprietary feed of news that's faster and more relevant than any other source. Try us for free and discover for yourself.

The type of stock you can hold forever.

See the rest of the story here.

Theflyonthewall.com is Wall Street's specialist in breaking equity news. Veteran traders build a proprietary feed of news that's faster and more relevant than any other source. Try us for free and discover for yourself.

Medical-Devices Sector Could Face Tougher Regulatory Pathway

There might be signs things are cooling off in China and Brazil.

Becton, Dickinson and Company (BDX) recently started expanding the recall of its catheters as a result of a manufacturing problem that could cause fatal embolisms or blood leakage. Becton is recalling its defective Q-Syte Luer Access Devices and Nexiva Closed IV Catheter Systems. The company started the initial recall of these products on Oct 28, ...

We maintain our Neutral rating on Alkermes, Inc. (ALKS) with a price target of $11.50. Alkermes is a drug delivery biotech company which uses its proprietary specialized drug delivery technologies to develop drugs for the treatment of central nervous system (CNS) disorders, alcoholism and diabetes. Alkermes has two approved products on the market. Its lead product, Risperdal [...]

(ALKS) Alkermes Retains Neutral Recommendation

We maintain our Neutral rating on Alkermes, Inc. (ALKS) with a price target of $11.50. Alkermes is a drug delivery biotech company which uses its proprietary specialized drug delivery technologies to develop drugs for the treatment of central nervous system (CNS) disorders, alcoholism and diabetes. Alkermes has two approved products on the market. Its lead product, Risperdal ...

We recently downgraded Baxter International Inc. (BAX) to Neutral. The stock was assigned a target price of $59 based on an approximate P/E multiple of 13.9x our fiscal 2010 earnings estimate of $4.25. Baxter recently reported fourth quarter and fiscal 2009 results. For the fourth quarter, earnings per share were $1.03, in line with the Zacks [...]

(BAX) Baxter International Downgraded to Neutral

We recently downgraded Baxter International Inc. (BAX) to Neutral. The stock was assigned a target price of $59 based on an approximate P/E multiple of 13.9x our fiscal 2010 earnings estimate of $4.25.  Baxter recently reported fourth quarter and fiscal 2009 results. For the fourth quarter, earnings per share were $1.03, in line with the Zacks ...

Tom Dorsey and Tammy DeRosier - What's Your Personal Value For The Next Decade

Schaeffer's analyst Morgan Searcy takes a look at news on the Street before the market open.

Two Veteran Wall Street Analysts discuss: (Vern:) BW, ABT, BMY; (Val:) ABC, BAX, JNJ

Schaeffer's analyst Morgan Searcy takes a look at news on the Street before the market open.

Schaeffer's analyst Morgan Searcy takes a look at news on the Street before the market open.